Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly & Co

Eli Lilly Could Swing $65.9 Billion After Earnings

Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro.

Stock Indexes Slip on Weakness in Megacap Technology Stocks

Stock Indexes Slip on Weakness in Megacap Technology Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.95%. December E-mini S&P futures (ESZ25 ) are down -0.38%, and December E-mini Nasdaq futures...

Stocks Pressured by Mixed Megacap Technology Earnings and Higher Bond Yields

Stocks Pressured by Mixed Megacap Technology Earnings and Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.47%. December E-mini S&P futures (ESZ25 ) are down -0.50%, and December E-mini Nasdaq futures...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning

The relentless rally in mega-cap tech is reviving memories of the dot-com bubble, as the Magnificent Seven continue to swell in value, leaving traditionally defensive sectors like healthcare in the dust.

MarketBeat Week in Review – 02/10 - 02/14

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

inkl

Read news from The Economist, FT, and more,
with one subscription

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Tech Stock Strength Lifts the Broader Market

Tech Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.16%. Strength in tech stocks today is lifting the broader market. Alphabet is up more...

Stocks Turn Lower on Negative Corporate News

Stocks Turn Lower on Negative Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. Stocks today gave up overnight gains and turned lower on some negative corporate news....

FDA approves Zepbound, a new obesity drug that will take on Wegovy

FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

Eli Lilly, insulin makers sued by California over prices

Eli Lilly & Co., Novo Nordisk AS and Sanofi were sued by California over insulin prices, which the state claims are inflated through unfair and deceptive practices and disproportionately affect low-income households and people of color.

Tribune News Service

Tech’s tectonic plates are shifting — will Twitter, Meta and the other giants survive?

Tech’s tectonic plates are shifting — will Twitter, Meta and the other giants survive?

Amid job losses and tumbling share prices, all the platforms once thought too big to fail are now fighting to stay relevant. From Twitter to Meta, change is afoot, says John Arlidge

Evening Standard

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

213,674 stories

Mark Zuckerberg

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Justice Department

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

418,784 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play